1Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst, 2000, 92:376-387.
2Gray NS, Wodicka L, Thunnissen AM, et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.Science, 1998, 281:533-538.
3Fry DW, Bedford DC, Harvey PH, et al. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J Biol Chem, 2001, 276:16617-16623.
4Chen YN, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A, 1999, 96:4325-4329.
5Fahraeus R, Lain S, Ball KL, et al. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene, 1998, 16: 587-596.
6Tamura K, Southwick EC, Kems J, et al. Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Res,2000, 60: 1317-1325.
7Tan Y, Xu M, Wang W, et al. IL-2 gene therapy of advanced lung cancer patients. Anticancer Res, 1996, 16:1993-1998.
8Heike Y, Takahashi M, Kanegae Y, et al. Interleukin-2 gene transduction into freshly isolated lung adenocarcinoma cells with adenoviral vectors. Hum Gene Ther, 1997, 8: 1-14.
9Sharma S, Wang J, Huang M, et al.Interleukin-7 gene transfer in nonsmall cell lung cancer decreases tumor proliferation, modifies cell surface molecule expression, and enhances antitumor reactivity. Cancer Gene Ther, 1996, 3: 302-313.
10Sharma S, Miller PW, Stolina M, et al. Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interhukin-7/herpes simplex thymidine kinasetransduced autologous tumor and ex vivo activated dendritic cells. Gene Ther, 1997, 4: 1361-1370.
